Palvella Therapeutics, Inc. (PVLA)

Price$157.24Cached quoteAs of 2026-09-05 10:25 UTC

AI: Fair-priced

Price checkThe valuation already discounts meaningful approval and launch success, leaving limited room for regulatory mistakes.

Palvella Therapeutics, listed on Nasdaq as PVLA, is valued at roughly $2.19 billion in equity and about $2.0 billion on an enterprise-value basis, which subtracts net cash. That is a substantial valuation for a company with no commercial product revenue yet. The stock also sits close to its recent highs after a large one-year re-rating. That makes the setup balanced: strong clinical and regulatory progress supports the premium, but much of the first product’s success appears anticipated.

Big pictureA large cash balance supports launch preparation, but losses are rising as the pipeline expands.

At June 30, Palvella held $250.6 million of cash, cash equivalents and short-term investments. First-half operating cash use was $23.7 million, while management guided to $85 million to $95 million of full-year 2026 cash expenses as manufacturing, trials and commercial preparation ramp. The balance sheet shows no conventional term debt, but it includes a $22.1 million long-term royalty agreement liability. Management says current liquidity funds at least twelve months, although spending should rise before and after a potential launch.

Business strengthLate-stage evidence, expedited FDA pathways and multiple indications give the QTORIN platform meaningful strategic leverage.

The core strength is QTORIN rapamycin, backed by positive Phase 3 SELVA results in microcystic lymphatic malformations and positive Phase 2 TOIVA data in cutaneous venous malformations. The lead program has Breakthrough Therapy, Fast Track and Orphan Drug designations, and the completed NDA targets a U.S. population the company estimates at more than 30,000 diagnosed patients. The business is not economically cyclical in the usual sense; results depend far more on FDA decisions, clinical readouts, launch adoption and biotech capital-market conditions.

What could change the storyApproval and strong uptake could unlock upside; delays, weak adoption or dilution could quickly reverse sentiment.

The bull case assumes FDA approval without another pivotal study, a timely standalone U.S. launch, meaningful penetration of the diagnosed microcystic-LM population, and continued success in venous malformations, angiokeratomas and DSAP. The bear case assumes FDA requests more evidence, payer or physician uptake is slower, later trials disappoint, or commercial spending outruns revenue. Capital allocation is another swing factor: February’s equity raise brought $215.8 million of net proceeds but increased shares, and nearly 1.4 million pre-funded warrants remained outstanding at midyear, creating additional dilution risk.

AI: News

Chief medical officer namedPalvella appointed longtime collaborator James Treat to lead medical strategy ahead of potential commercialization.

On September 9, Palvella appointed James R. Treat, M.D., as chief medical officer, effective December 21. Treat is a pediatric dermatologist with extensive vascular-anomaly experience and has been a long-time Palvella clinical collaborator and QTORIN trial investigator. The hire adds disease-specific medical leadership as the company moves its lead program through FDA review and prepares for a possible first-half 2027 commercial launch while advancing additional QTORIN indications.

NDA submission completedPalvella finished its rolling FDA application for QTORIN rapamycin in microcystic lymphatic malformations.

On August 31, Palvella completed its rolling New Drug Application seeking approval of QTORIN rapamycin for microcystic lymphatic malformations. FDA had previously granted Breakthrough Therapy, Fast Track and Orphan Drug designations to the program, and rolling review allows completed sections to be evaluated earlier. The company continues preparing for a standalone U.S. launch in the first half of 2027 if approved, making FDA acceptance and review timing the next major value-driving milestones.

Quarterly burn acceleratedSecond-quarter spending rose as manufacturing, regulatory work and launch preparation expanded before possible approval.

On August 4, Palvella reported a second-quarter net loss of $21.9 million, versus $9.5 million a year earlier. Research and development expense rose to $12.5 million, while general and administrative expense increased to $8.9 million. Liquidity remained strong at $250.6 million at quarter-end. Management also reiterated plans to start a Phase 3 cutaneous venous-malformation trial in the fourth quarter and a Phase 2 QTORIN pitavastatin study in the second half.

Breakthrough request deferredFDA did not grant breakthrough status for cutaneous venous malformations, prompting a planned resubmission.

The August 4 quarterly filing disclosed that FDA had decided in July not to grant Breakthrough Therapy designation at that time for QTORIN rapamycin in cutaneous venous malformations. Palvella plans to resubmit with TOIVA patient-interview transcripts and new 24-week data. The program still has Fast Track status, and the company continues planning a Phase 3 trial. The decision is a regulatory setback, but it does not amount to a rejection of the underlying drug program.

Loading local price history

Revenue

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Net income

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Free cash flow

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Total cash / debt

CashTotal debt

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014 · Dec 31	2014 · Jun 30	2013
Revenue	$0	$0	$38.7M	$25.5M	$27.9M	$23.9M	$43.6M	$27.2M	$25.3M	$5.8M	$2.9M	$5.4M	$0	$12.4M
Research & development	$22.8M	$8.2M	$8.8M	$53.0M	$66.7M	$46.5M	$55.0M	$41.5M	$22.3M	$19.7M	$8.2M	$5.6M	—	$9.4M
Operating expenses	$38.6M	$14.1M	$11.9M	$69.4M	$83.2M	$63.2M	$73.4M	$59.9M	$39.9M	$28.6M	$16.6M	$12.6M	$15,712	$11.9M
Operating income	−$38.6M	−$14.1M	−$11.9M	−$43.5M	−$51.8M	−$33.9M	−$27.2M	−$30.8M	−$14.6M	−$22.8M	−$13.7M	−$7.2M	−$15,712	$553,826
Operating margin	—	—	−30.66%	−170.69%	−185.51%	−141.86%	−62.22%	−113.15%	−57.74%	−390.31%	−466.62%	−134.17%	—	4.46%
EBITDA	−$35.9M	−$13.1M	−$10.0M	−$40.7M	−$49.4M	−$31.8M	−$26.6M	−$30.3M	−$14.2M	−$22.4M	−$13.4M	−$6.8M	—	$938,503
EBITDA margin	—	—	−25.74%	−159.82%	−176.71%	−133.08%	−60.85%	−111.06%	−56.28%	−384.12%	−456.12%	−127.33%	—	7.55%
Net income	−$41.7M	−$17.4M	$18.7M	−$33.3M	−$45.7M	−$37.2M	−$25.5M	−$26.8M	−$17.6M	−$22.8M	−$14.1M	−$9.8M	−$15,712	$66,196
Net profit margin	—	—	48.28%	−130.66%	−163.70%	−155.70%	−58.35%	−98.19%	−69.82%	−391.00%	−479.50%	−183.59%	—	0.53%
Basic EPSper basic share	-$3.71	-$7.83	$2.19	-$36.00	-$56.80	-$54.40	-$44.80	-$40.00	-$32.00	-$44.00	-$32.80	-$56.80	$0.00	$0.80
Diluted EPSper diluted share	-$3.71	-$7.83	$2.17	-$2.46	-$56.80	-$54.40	-$44.80	-$40.00	-$32.00	-$44.00	-$32.80	-$56.80	$0.00	$0.80

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

7.89%of listed shares

MONTANOVA CAPITAL, LLC1.14M shares · Jun 30, 2026

View holders

Top 20 reported holders of PVLA
Holder	% owned
MONTANOVA CAPITAL, LLC	7.89%1.14M shares
JENNISON ASSOCIATES LLC	6.67%960.62K shares
BlackRock, Inc.	6.38%918.36K shares
Frazier Life Sciences Management, L.P.	6.13%882.4K shares
First Light Asset Management, LLC	5.36%771.9K shares
BVF INC/IL	4.67%672.79K shares
STATE STREET CORP	4.54%653.17K shares
PRICE T ROWE ASSOCIATES INC /MD/	4.44%638.87K shares
VANGUARD CAPITAL MANAGEMENT LLC	3.57%513.79K shares
FRONTIER CAPITAL MANAGEMENT CO LLC	3.33%478.83K shares
FEDERATED HERMES, INC.	3.01%433.02K shares
Woodline Partners LP	2.21%317.52K shares
ORBIMED ADVISORS LLC	2.03%292.36K shares
GEODE CAPITAL MANAGEMENT, LLC	1.92%276.16K shares
Siren, L.L.C.	1.79%257.49K shares
PRIMECAP MANAGEMENT CO/CA/	1.78%256.18K shares
ALLIANCEBERNSTEIN L.P.	1.76%253.17K shares
EVENTIDE ASSET MANAGEMENT, LLC	1.61%231.48K shares
EMERALD ADVISERS, LLC	1.59%229.49K shares
FMR LLC	1.49%214.84K shares

Percentages use 14.4M shares of this listed class outstanding on Jun 30, 2026.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys10$1.09M disclosed value

Sells (SEC code S)21$3.55M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Jun 17, 2026Form 4 · 10b5-1	Goin KathleenChief Operating Officer	SellCommon Stock	25	$112.23	$2.8K	0
Jun 17, 2026Form 4 · 10b5-1	Goin KathleenChief Operating Officer	SellCommon Stock	1.9K	$111.31	$210.0K	25
Jun 17, 2026Form 4 · 10b5-1	Goin KathleenChief Operating Officer	SellCommon Stock	2.4K	$110.26	$263.5K	1.9K
May 20, 2026Form 4 · 10b5-1	Goin KathleenChief Operating Officer	SellCommon Stock	48	$111.90	$5.4K	0
May 20, 2026Form 4 · 10b5-1	Goin KathleenChief Operating Officer	SellCommon Stock	891	$111.30	$99.2K	48

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about PVLA yet. Start the conversation.

Write the first post

Palvella Therapeutics, Inc. (PVLA)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.